Sequence Symmetry Analysis and Disproportionality Analyses: What Percentage of Adverse Drug Reaction do they Signal?
|Izyan A Wahab*, Nicole L Pratt, Lisa M Kalisch and Elizabeth E Roughead|
|School of Pharmacy and Medical Sciences, Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, Adelaide, South Australia, Australia|
|*Corresponding Author :||Izyan A Wahab
QUMPRC, Sansom Institute
School of Pharmacy and Medical Sciences
University of South Australia, GPO Box 2471
Adelaide 5001, South Australia, Australia
Fax: +61 8 8302 1087
E-mail: [email protected]
|Received July 23, 2013; Accepted September 07, 2013; Published September 09, 2013|
|Citation: Wahab IA, Pratt NL, Kalisch LM, Roughead EE (2013) Sequence Symmetry Analysis and Disproportionality Analyses: What Percentage of Adverse Drug Reaction do they Signal?. Adv Pharmacoepidemiol Drug Saf 2:140. doi:10.4172/2167-1052.1000140|
|Copyright: © 2013 Wahab IA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: Sequence Symmetry Analysis (SSA) is a method to detect Adverse Event (AE) signals using administrative claims data. Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) are methods to detect AE signals using spontaneous reporting data. The proportion of AEs detected by all four methods is unknown. Objective: To determine sensitivity, specificity and predictive values of SSA, PRR, ROR and BCPNN for a set of medicine-AE pairs. Methods: All AEs identified in published Randomised Controlled Trials (RCTs) and Product Information (PI) were extracted for 19 medicines. Gold standard positive AEs were events identified in powered RCTs and gold standard negative AEs were events not listed in the PI for that medicine or any other medicines in the class. SSA was performed for each medicine-AE pairs using Australian Goverrnment Department of Veterans Affairs’ data, while the PRR, ROR and BCPNN, was calculated using the Food and Drug Administration Adverse Events Reporting System data. Results: A total of 157 medicine-AE pairs (43 positive and 114 negative) were identified and tested. SSA, PRR, ROR and BCPNN had a sensitivity of 65%, 1 9%, 49% and 51% respectively. Specificities across all methods were similar; 89%-97%. Thirty percent of true positive pairs were detected by all methods. SSA detected an additional 35% different true positive pairs while PRR, ROR and BCPNN methods detected an additional 21% different true positive pairs. Conclusions: Using the combination of signalling methods and data sources, more adverse drug reactions can be detected and could potentially strengthen the safety surveillance of post-marketing medicine.